Gene therapy refers to the use of a specific gene encoding a protein as a means of treating a human disease1. Initially, the potential use of such a therapy was suggested to be simple genetic diseases where the individual's disease was caused by a defective copy of a particular gene. The disease might then be treated by providing a functional copy of that gene to complement the defect.
However, it has now become clear that gene therapy could also be used in diseases which do not have a genetic component or where that genetic component has not yet been characterized. In such cases the gene would be one whose protein product could relieve the symptoms of the disease. It is this kind of gene therapy that currently has the greatest potential applicability in the nervous system. Thus, in neurodegenerative diseases such as motor neuron disease or Alzheimer's disease one could supply the gene encoding a neurotrophic factor which could promote survival of neurons that would otherwise die. Indeed, therapeutic benefit has been observed in an animal model of motor neuron disease when the genes encoding neurotrophin-3 and ciliary neurotrophic factor were delivered with virus vectors2. Similarly, the damage that follows stroke might be lessened by delivering genes encoding protective proteins such as the heat-shock proteins3.
Amongst the diseases of the nervous system, Parkinson's disease is a prime candidate for application of the technique. The relative success of fetal transplants, in animal models and human patients4, offers encouragement to specific interventions by this new route.
THERAPEUTIC GENES FOR PARKINSON'S DISEASE
Tyrosine hydroxylase Given that Parkinson's disease results from a loss of dopaminergic neurons, one means of treating the disease would be to enhance the supply of dopamine, and this effect is likely to be the reason for the beneficial effects noted with fetal transplants. An obvious means of enhancing dopamine production would be to increase the levels of the tyrosine hydroxylase, which is the rate-limiting step of the dopaminergic pathway. Clearly, however, tyrosine hydroxylase cannot be supplied simply as a protein since it will not be taken up by the cells which require it. Therefore the tyrosine hydroxylase must be introduced either within genetically modified cells that produce dopamine or by direct delivery of the tyrosine hydroxylase gene. Since optimal tyrosine hydroxylase activity may be obtainable only in the presence of sufficient levels of tetrahydrobiopterin, it may also be necessary to introduce the gene encoding GTP-cyclohydrolase 1, which is the rate-limiting step in the tetrahydrobiopterin synthesizing pathway5.
Neurotrophic factors
An additional therapeutic strategy would be to slow or halt the death of dopaminergic neurons, which causes inexorable deterioration in Parkinson's disease. One important survival factor for these neurons is glial-derived neurotrophic factor (GDNF), administration of which has proved of therapeutic benefit both in the 6-hydroxydopamine rat model of Parkinson's disease and in primate models of the disease6'7.
These studies involved the delivery of GDNF itself to the animal brain, where it acts by binding to a cell surface receptor; thus, unlike tyrosine hydroxylase, it does not need to enter the cell to be effective. In removed without substantially affecting viral growth and hence could accommodate 30-40 kilobases of foreign genetic material. This is of particular importance in Parkinson's disease since effective therapy will probably require the delivery of multiple genes for example, GDNF to promote survival of the remaining dopaminergic neurons, and tyrosine hydroxylase to stimulate further dopamine production. As noted earlier, for an optimal effect of tyrosine hydroxylase one probably also needs to deliver the gene encoding GTP cyclohydrolase 1, to allow production of tetrahydrobiopterin5. Similarly, treatment of an animal model of motor neuron disease required the use of separate adenovirus vectors encoding neurotrophin-3 and ciliary neurotrophic factor2, whereas the genes encoding these two factors could readily have been delivered in a single HSV vector. This system allows foreign DNA sequences to be readily introduced into the HSV genome and the resulting recombinant viruses can be purified easily17.
DRAWBACKS OF HSV AS A VECTOR
As noted above, HSV normally replicates in epithelial cells, producing cold sores or genital sores. More seriously, HSV introduced into the brain will replicate and cause a lethal encephalitis. Clearly therefore, the virus must be disabled in some way if it is to be used as a vector. Such disablement is required not only where the gene of interest is introduced directly into the HSV vector but also in the amplicon system where the helper virus must be disabled if damaging effects are not to occur.
How can the virus be disabled without hampering its growth in culture to the extent that viral stocks cannot be prepared? The simplest method is to remove genes whose protein products are required for lytic replication in all cell types. Thus, viruses have been produced that lack either of the essential immediate early genes encoding ICP418 or ICP2719. Removal of either of these genes renders the virus incapable of lytic replication in all cell types so that it does not cause encephalitis when directly injected into the brain. The disadvantage of this method is that, to grow the virus, the gene encoding ICP4 or ICP27 must be provided in specially constructed cell lines so as to complement the defect. In doing this it is essential to ensure that there is no overlap between the virus gene in the cell line and the sequences remaining in the virus itself, since otherwise recombination will occur to generate a wild-type virus.
HSV AS A VECTOR FOR PARKINSON'S DISEASE
We have prepared several different derivatives of a disabled virus lacking functional genes encoding ICP27 and ICP34.5. These contain different combinations of genes whose protein products, tyrosine hydroxylase or GDNF, may be of therapeutic benefit in Parkinson's disease. These viruses have been tested in the rat 6-hydroxydopamine model of Parkinson's disease, in which dopaminergic neurons are destroyed on one side of the brain by injection of 6- hydroxydopamine into the substantia nigra. The effect of striatal injection of the virus carrying the potential therapeutic gene on the rotational behaviour induced by a subsequent injection of apomorphine is then assessed and compared with the effect of control virus. Figure 2 shows a result when viruses encoding either tyrosine hydroxylase . . Figure 2 Effect of control virus (pR2O.9) or viruses encoding either tyrosine hydroxylase (TH) or GDNF plus TH on apomorphine-induced rotation in rats given virus six weeks after unilateral injection of 6-hydroxydopamine. Q=pR2O.9; EJ=TH; A=TH/GDNF alone or GDNF and tyrosine hydroxylase were injected six weeks after the 6-hydroxydopamine lesion. Both viruses reduced rotational behaviour for seven to eight weeks after injection. Note that such experiments, in which viruses are injected after the 6-hydroxydopamine lesion, mimic the situation in human disease, where therapy would have to begin after the onset of dopaminergic neuronal death. Clearly, further studies are required in animals to determine the optimal combination of therapeutic genes. Similarly, it will be necessary to test the effect on safety and toxicity of further viral disablement, such as removal of the essential immediate-early gene encoding ICP4 which will probably be required for human use. However, once these further studies have been completed, we can envisage clinical trials with these viruses, particularly where drug therapy has failed.
One potential difficulty with human use of these viruses is that most people, unlike animals, have latent wild type HSV, predominantly in the dorsal root ganglia of peripheral nerves but also in the central nervous system. Hence, injection of disabled recombinant virus could result in reactivation of potentially dangerous wild-type virus or recombination with it. However, this seems unlikely to occur. Work in animals with wild-type HSV latent in their central or peripheral nervous system has not shown any reactivation following injection ofdisabled virus22. Similar results were obtained in a phase I clinical trial23 in which patients with glioma had intracranial injection of a virus lacking only ICP34.5, which is expected to replicate and kill the dividing glioma cells but not non-dividing neurons; although the great majority of the patients in this study had latent wild-type HSV, no reactivation of the wild-type virus was observed. No other damaging effects were noted in this trial despite the fact that, to achieve the effect of killing tumour cells, the virus has only a single disabling mutation which does not prevent replication in all cell types.
CONCLUSION
The unique features of HSV as a gene delivery tool for the nervous system are its ability to establish symptomless latent infections in neuronal cells and its ability to accept multiple inserted genes. The effective disablement of the virus and its modification to allow long-term expression has already allowed testing of the effect of particular gene products in neuronal cells24'25 as well as demonstration of therapeutic effects in a rat model of Parkinson's disease. Further disablement of the virus and combinations of several different genes may ultimately result in a vector that can be used in Parkinson's disease, and perhaps other diseases of the nervous system.
